249 related articles for article (PubMed ID: 33811756)
1. Beneficial effect of Arbidol in the management of COVID-19 infection.
Jie X; Hongmei Y; Ping F; Kuikui Z; Bohan Y; Rui M
Aging (Albany NY); 2021 Apr; 13(7):9253-9264. PubMed ID: 33811756
[TBL] [Abstract][Full Text] [Related]
2. Prolonged SARS-CoV-2 Viral Shedding in Patients with COVID-19 was Associated with Delayed Initiation of Arbidol Treatment and Consulting Doctor Later: A Retrospective Cohort Study.
He XL; Zhou YY; Fu W; Xue YE; Liang MY; Yang BH; Ma WL; Zhou Q; Chen L; Zhang JC; Wang XR
Curr Med Sci; 2021 Dec; 41(6):1096-1104. PubMed ID: 34515914
[TBL] [Abstract][Full Text] [Related]
3. Clinical features and efficacy of antiviral drug, Arbidol in 220 nonemergency COVID-19 patients from East-West-Lake Shelter Hospital in Wuhan: a retrospective case series.
Gao W; Chen S; Wang K; Chen R; Guo Q; Lu J; Wu X; He Y; Yan Q; Wang S; Wang F; Jin L; Hua J; Li Q
Virol J; 2020 Oct; 17(1):162. PubMed ID: 33097047
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the antiviral effect of Arbidol and Chloroquine in treating COVID-19.
Li M; Yu T; Zhu J; Wang Y; Yang Y; Zhao K; Yi Y; He J; Li C; He J
Ann Palliat Med; 2021 Mar; 10(3):3307-3312. PubMed ID: 33849115
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Arbidol for COVID-19 Prevention in Health Professionals.
Yang C; Ke C; Yue D; Li W; Hu Z; Liu W; Hu S; Wang S; Liu J
Front Public Health; 2020; 8():249. PubMed ID: 32574310
[No Abstract] [Full Text] [Related]
6. Liver injury after antiviral treatment of critically ill patients with COVID-19: a single-centered retrospective cohort study.
Ruan X; Lu X; Wang K; Zhang B; Wang J; Li Y; Wang J; Xu Z; Yan F
Ann Palliat Med; 2021 Mar; 10(3):2429-2438. PubMed ID: 33440980
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of arbidol versus lopinavir/ritonavir in the treatment of coronavirus disease 2019.
Yu M; Wang DC; Li S; Lei YH; Wei J; Huang LY
J Med Virol; 2022 Apr; 94(4):1513-1522. PubMed ID: 34837230
[TBL] [Abstract][Full Text] [Related]
8. Antiviral drugs arbidol and interferon alpha-1b contribute to reducing the severity of COVID-19 patients: a retrospective cohort study.
Yin P; Meng J; Chen J; Gao J; Wang D; Liu S; Guo Q; Zhu M; Zhang G; Liu Y; Li Y; Zhang G
Virol J; 2021 Jul; 18(1):142. PubMed ID: 34238341
[TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of Shufeng Jiedu Capsules combined with umifenovir (Arbidol) in the treatment of common-type COVID-19: a retrospective study.
Chen J; Lin S; Niu C; Xiao Q
Expert Rev Respir Med; 2021 Feb; 15(2):257-265. PubMed ID: 32941741
[TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of Ixekizumab and Antiviral Treatment for Patients with COVID-19: A structured summary of a study protocol for a Pilot Randomized Controlled Trial.
Liu P; Huang Z; Yin M; Liu C; Chen X; Pan P; Kuang Y
Trials; 2020 Dec; 21(1):999. PubMed ID: 33276811
[TBL] [Abstract][Full Text] [Related]
11. Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: A pilot retrospective study.
Lan X; Shao C; Zeng X; Wu Z; Xu Y
Int J Clin Pharmacol Ther; 2021 May; 59(5):378-385. PubMed ID: 33624583
[TBL] [Abstract][Full Text] [Related]
12. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study.
Deng L; Li C; Zeng Q; Liu X; Li X; Zhang H; Hong Z; Xia J
J Infect; 2020 Jul; 81(1):e1-e5. PubMed ID: 32171872
[TBL] [Abstract][Full Text] [Related]
13. Arbidol combined with the Chinese medicine Lianhuaqingwen capsule versus arbidol alone in the treatment of COVID-19.
Liu L; Shi F; Tu P; Chen C; Zhang M; Li X; Li C
Medicine (Baltimore); 2021 Jan; 100(4):e24475. PubMed ID: 33530261
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy of methylprednisolone and the combined use of lopinavir/ritonavir with arbidol in treatment of coronavirus disease 2019.
Xia Q; Dai W; Xu K; Ni Q; Li Y; Liu J; Zhao H; Guo Y; Yu L; Yi P; Su J; Lang G; Tao J; Shi D; Wu W; Wu X; Xu Y; Xu M; Yu L; Wang X; Cai H; Fang Q; Zhou J; Qiu Y; Li L
J Med Virol; 2021 Jul; 93(7):4446-4453. PubMed ID: 33448426
[TBL] [Abstract][Full Text] [Related]
15. [The efficacy and safety of lopinavir/ritonavir and arbidol in patients with coronavirus disease 2019].
Wen CY; Xie ZW; Li YP; Deng XL; Chen XT; Cao Y; Ou X; Lin WY; Li F; Cai WP; Li LH
Zhonghua Nei Ke Za Zhi; 2020 Aug; 59(8):605-609. PubMed ID: 32388937
[No Abstract] [Full Text] [Related]
16. Arbidol/IFN-α2b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study.
Xu P; Huang J; Fan Z; Huang W; Qi M; Lin X; Song W; Yi L
Microbes Infect; 2020; 22(4-5):200-205. PubMed ID: 32445881
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of arbidol in COVID-19 patients: A retrospective study.
Wei S; Xu S; Pan YH
World J Clin Cases; 2021 Sep; 9(25):7350-7357. PubMed ID: 34616801
[TBL] [Abstract][Full Text] [Related]
18. Safety of protease inhibitors and Arbidol for SARS-CoV-2 pneumonia in Zhejiang Province, China.
Guo YZ; Xu KJ; Li YT; Fu JD; Xu M; Yu L; Sheng JF; Zhu B
J Zhejiang Univ Sci B; 2020 Dec.; 21(12):948-954. PubMed ID: 33843160
[TBL] [Abstract][Full Text] [Related]
19. Associated risk factors with disease severity and antiviral drug therapy in patients with COVID-19.
Gong X; Kang S; Guo X; Li Y; Gao H; Yuan Y
BMC Infect Dis; 2021 Jun; 21(1):549. PubMed ID: 34112084
[TBL] [Abstract][Full Text] [Related]
20. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study.
Lian N; Xie H; Lin S; Huang J; Zhao J; Lin Q
Clin Microbiol Infect; 2020 Jul; 26(7):917-921. PubMed ID: 32344167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
